ArticleScientific reports2025
Unlocking the therapeutic potential of Catharanthus roseus leaves via in-vitro, in-vivo, and in-silico study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vinca Extract Infused Silk Fibroin Hydrogel for Treatment of Artificially Induced Diabetic Foot Ulcer in Murine Model.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catharanthus roseus (L.) (CR), is a perennial flowering herb, has traditionally been used by local populations in South Asia, Africa, China and Malaysia to treat diabetes, cancer and microbial infection. The principal objective of this study was to investigate the antidiabetic, antilipidemic and antiarthritic effects of methanol (MCR) and ethanol (ECR) extracts and dichloromethane fraction (DCR) of Catharanthus roseus leaves by in-vitro, in-vivo, and in-silico model. The in-vivo antihyperglycemic activity of C. roseus was explored in streptozotocin (STZ)-induced Type- 1 diabetic mice model. MCR, ECR and DCR exhibited a significant ability to lower fasting blood glucose levels and normalized the altered body weight when treatment was carried out for 20 days in a dose-dependent manner. Among the experimental samples, ECR at 200 mg/kg (4.95 ± 0.31 mmol/L) showed greater fasting blood glucose lowering activity than the standard drugs metformin (6.8 ± 0.34 mmol/L), and glibenclamide (5.20 ± 0.29 mmol/L). MCR at 200 mg/kg, likewise significantly (p < 0.001) reduced the blood glucose (5.70 ± 0.12 mmol/L) compared to the control at day 20. The lipid profile (LDL, HDL, TG, and TC) of diabetic mice was significantly reduced by ECR in a biochemical study compared to the control group. The in-vitro antidiabetic study revealed a dose-dependent hypoglycemic potential of the extracts and fraction; where ECR showed the highest α-amylase and α-glucosidase inhibitory effects with the IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.